HomeMarketDon't be afra...

Don’t be afraid of Cymabay Therapeutics Inc (CBAY) Stock despite uncertainty and doubt

UBS raised the price target for the Cymabay Therapeutics Inc (NASDAQ:CBAY) stock to “a Buy”. The rating was released on August 14, 2023, according to finviz.

The latest trade, Performances and Moving Averages give us the following Picture

The share price of Cymabay Therapeutics Inc (NASDAQ:CBAY) raised 1.63% to close Monday’s market session at $18.66, higher as compared to yesterday’s close. The stock price fluctuated between $17.77 and $18.81 throughout the trading session with the volume trading being 1890516 shares, which represented a significant variation when compared to the three months average volume of 2.31 million shares. The firm’s stock price fluctuated 10.61% within the last five trades and 37.11% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price increased 113.01% in the last 6 months and 42.88% was added to its value over the previous 3 months. CBAY stock is trading at a margin of 14.46%, 21.18% and 62.96% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


As of the close of trading, CBAY deals in the Healthcare domain. The stock is trading 0.00 percent below its 52-week high and 488.64 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is 318. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.

What Does Cymabay Therapeutics Inc’s Profitability and Valuation Ratios Tell Us About the Stock?

With regard to the profitability of the company, the operating margin is currently at -266.50 percent and the profit margin is -290.50 percent, and the company has reported a gross margin of 97.39 percent. The profit margin, also known as the revenue ratio or gross profit ratio, is an efficiency figure used to estimate the business’s profitability by comparing net income and sales. The higher the number, the more profits are generated for the company and vice versa.

The stock’s market cap achieved a total value of $2.12 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 68.22 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 6.48, which equates the market value of a stock with its book value.

Is Insider Trading a Real Thing?

Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 4.65 percent of Cymabay Therapeutics Inc shares are owned by insiders, and 93.33 percent are held by financial institutions. McWherter Charles, the President of R&D at Cymabay Therapeutics Inc (CBAY) has sold 11,342 shares of firm on Nov 17 at a price of $18.28 against the total amount of $0.21 million. In another inside trade, Quinlan Paul T, General Counsel of Cymabay Therapeutics Inc (NASDAQ:CBAY) sold 5,000 shares of the firm on Nov 15 for a total worth of $86889.0 at a price of $17.38. An inside trade which took place on Oct 18, President of R&D of Cymabay Therapeutics Inc McWherter Charles sold 21,743 shares of firm against total price of $0.31 million at the cost of $14.07 per share.



Please enter your comment!
Please enter your name here

Recent Post

It’s not the right ...

Top-line Growth is Likely...

Does U.S. Bancorp. (USB) ...